REPROCELL offers functional validation of disease targets using our human-relevant systems. Investigate the target's potential as a drug using fresh patient tissue or patient-specific iPSC-derived disease model cells.
|COPD Lung||Healthy Lung|
Custom iPSCs can be created by reprogramming patient samples (Fibroblast, Blood, Urine, etc.) with REPROCELL Stemgent’s exclusive StemRNA™-3rd Gen footprint-free RNA technology. Patient-specific iPSCs are a self-renewing and expandable cell population with potential to differentiate into virtually any cell type.
We also have the ability to provide precision genome-edited cells by working with our leading industry partners. The ability to model human diseases using iPSCs has revolutionized the ways in which we study monogenic, complex and epigenetic disorders, as well as early- and late-onset diseases.
REPROCELL offers iPSC-derived differentiated cardiac cells, hepatocytes, and neurons suitable for use in basic research as model systems for a variety of applications. Unlike primary cells which may come from random donors with variable genetic backgrounds, these iPSC-derived cells have strong lot-to-lot performance consistency.
REPROCELL also has the ability to prepare customized versions of iPSC-derived cell types as required.